Gonadorelin vs MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Gonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profileMGF
MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical loading (exercise, especially eccentric loading). Unlike circulating IGF-1 which is produced primarily by the liver, MGF is generated within the muscle itself and acts locally to activate satellite cells (muscle stem cells) — the cells responsible for muscle repair, growth, and adaptation. It is considered the primary local anabolic signal generated by resistance training.
Full profile| Gonadorelin | MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse | Mechano Growth Factor, IGF-1Ec, Insulin-like Growth Factor splice variant |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 50mcg–200mcg mcg, 2–3x per week subcutaneous | 100mcg–300mcg mcg, Post-workout (within 30–60 minutes of training), 3–4x weekly |
| Administration | Subcutaneous injection, Intranasal (pulsatile delivery) | Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution) |
| Key side effects | Injection site reactions, Headache, Nausea, Flushing | Localized muscle swelling at injection site (normal response), Hypoglycemia (less pronounced than IGF-1 DES but present), Very short half-life means side effects are brief, Potential overuse injury if post-workout injection is used consistently without adequate recovery |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: Gonadorelin is research-stage, while MGF is preclinical only.
- Administration: Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery); MGF — Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution).
- Frequency: Gonadorelin is typically 2–3x per week subcutaneous; MGF is Post-workout (within 30–60 minutes of training), 3–4x weekly.
- Research depth: this profile cites 2 sources for Gonadorelin vs 3 for MGF.
How each works
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
MGF
MGF is encoded by the IGF-1 gene but produced via alternative splicing that generates a unique 49-amino acid C-terminal E-peptide (Ec peptide). The Ec peptide has distinct biological activity from the IGF-1 domain — it directly activates satellite cell proliferation through a receptor pathway separate from the standard IGF-1R. Studies in rodents show that local MGF injection produces significant muscle hypertrophy in the injected limb without systemic IGF-1 elevation. MGF expression spikes within 30 minutes of resistance exercise and declines over 24–48 hours — aligning precisely with the post-exercise anabolic window.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.